Literature DB >> 6326153

beta-Endorphin: characterization of binding sites specific for the human hormone in human glioblastoma SF126 cells.

M Westphal, C H Li.   

Abstract

The established human glioblastoma cell line SF126 was found to bind tritiated human beta-endorphin (beta h-EP) in a saturable fashion. From displacement studies, the ED50 was estimated to be about 2.5 nM. The Kd was estimated as 1.9 X 10(-9) M and Scatchard analysis showed a biphasic pattern with a predominant low-affinity component. Binding reached a maximum at about 90 min at 22 degrees C and was instantaneously reversible. Tritiated [D-Ala2,D-Leu5]enkephalin and tritiated dihydromorphine did not bind to the cells. Sodium at a concentration of 150 mM decreased the specific binding by 80%. The interaction with the cellular binding site appeared to be mediated by the COOH-terminal segment of beta h-EP, as beta h-EP-(6-31) retained a high potency for displacing tritiated beta h-EP, and beta h-EP-(1-27) has no activity. Camel beta-EP was only about 1% as active as the human hormone.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6326153      PMCID: PMC345185          DOI: 10.1073/pnas.81.9.2921

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  Statistical analysis of radioligand assay data.

Authors:  D Rodbard; G R Frazier
Journal:  Methods Enzymol       Date:  1975       Impact factor: 1.600

2.  Synthesis and analgesic activity of human beta-endorphin.

Authors:  C H Li; D Yamashiro; L F Tseng; H H Loh
Journal:  J Med Chem       Date:  1977-03       Impact factor: 7.446

3.  Proliferation of glial-derived cells in defined media.

Authors:  A Michler-Stuke; J E Bottenstein
Journal:  J Neurosci Res       Date:  1982       Impact factor: 4.164

4.  beta-Endorphin.

Authors:  C H Li
Journal:  Cell       Date:  1982-12       Impact factor: 41.582

5.  beta-Endorphin: complete primary structure is required for full analgesic activity.

Authors:  C H Li; L F Tseng; D Yamashiro
Journal:  Biochem Biophys Res Commun       Date:  1978-11-29       Impact factor: 3.575

6.  beta-endorphin: synthesis and biological activity of shortened peptide chains.

Authors:  C H Li; D Yamashiro; L F Tseng; H H Loh
Journal:  Int J Pept Protein Res       Date:  1978-02

7.  Beta-Endorphin. Synthesis and radioreceptor-binding activity of the ostrich hormone.

Authors:  D Yamashiro; R G Hammonds; C H Li
Journal:  Int J Pept Protein Res       Date:  1982-03

8.  Stem cell studies of human malignant brain tumors. Part 1: Development of the stem cell assay and its potential.

Authors:  M L Rosenblum; M A Gerosa; C B Wilson; G R Barger; B F Pertuiset; N de Tribolet; D V Dougherty
Journal:  J Neurosurg       Date:  1983-02       Impact factor: 5.115

9.  beta-Endorphin: characteristics of binding sites in the mouse brain.

Authors:  S Y Lin-Shiau; R G Hammonds; C H Li
Journal:  Eur J Pharmacol       Date:  1983-02-18       Impact factor: 4.432

10.  beta-endorphin: characteristics of binding sites in the rabbit cerebellar and brain membranes.

Authors:  C L Ho; R G Hammonds; C H Li
Journal:  Biochem Biophys Res Commun       Date:  1983-03-29       Impact factor: 3.575

View more
  4 in total

1.  Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells.

Authors:  C L Gladson; D A Cheresh
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

2.  Characterization of solubilized human and rat brain beta-endorphin-receptor complex.

Authors:  D M Helmeste; C H Li
Journal:  Proc Natl Acad Sci U S A       Date:  1986-01       Impact factor: 11.205

3.  Preparation of [125I-Tyr27,Leu5]beta h-endorphin and its use for crosslinking of opioid binding sites in human striatum and NG108-15 neuroblastoma-glioma cells.

Authors:  D M Helmeste; R G Hammonds; C H Li
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

4.  Endomorphin 1 and endomorphin 2 suppress in vitro antibody formation at ultra-low concentrations: anti-peptide antibodies but not opioid antagonists block the activity.

Authors:  Benito Anton; Phillipe Leff; Juan C Calva; Rodolfo Acevedo; Alberto Salazar; Maura Matus; Lenin Pavón; Martin Martinez; Joseph J Meissler; Martin W Adler; John P Gaughan; Toby K Eisenstein
Journal:  Brain Behav Immun       Date:  2008-04-18       Impact factor: 7.217

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.